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ABSTRACT
Objectives TYK2 is a common genetic risk factor for
several autoimmune diseases. This gene encodes a
protein kinase involved in interleukin 12 (IL-12) pathway,
which is a well-known player in the pathogenesis of
systemic sclerosis (SSc). Therefore, we aimed to assess
the possible role of this locus in SSc.
Methods This study comprised a total of 7103 patients
with SSc and 12 220 healthy controls of European
ancestry from Spain, USA, Germany, the Netherlands,
Italy and the UK. Four TYK2 single-nucleotide
polymorphisms (V362F (rs2304256), P1104A
(rs34536443), I684S (rs12720356) and A928V
(rs35018800)) were selected for follow-up based on the
results of an Immunochip screening phase of the locus.
Association and dependence analyses were performed by
the means of logistic regression and conditional logistic
regression. Meta-analyses were performed using the
inverse variance method.
Results Genome-wide signiﬁcance level was reached
for TYK2 V362F common variant in our pooled analysis
(p=3.08×10−13, OR=0.83), while the association of
P1104A, A928V and I684S rare and low-frequency
missense variants remained signiﬁcant with nominal
signals (p=2.28×10−3, OR=0.80; p=1.27×10−3,
OR=0.59; p=2.63×10−5, OR=0.83, respectively).
Interestingly, dependence and allelic combination
analyses showed that the strong association observed for
V362F with SSc, corresponded to a synthetic association
dependent on the effect of the three previously
mentioned TYK2 missense variants.
Conclusions We report for the ﬁrst time the
association of TYK2 with SSc and reinforce the relevance
of the IL-12 pathway in SSc pathophysiology.
INTRODUCTION
Systemic sclerosis (SSc) is an autoimmune disease
that involves extensive ﬁbrosis in the skin and dif-
ferent internal organs, abnormalities of the vascular
system and immune imbalance with autoantibody
production, particularly anticentromere autoanti-
bodies (ACA) and antitopoisomerase autoantibodies
(ATA). The aetiology of the disease is largely
unknown, although both environmental and
genetic factors are thought to be involved in the
disease development.1
Large genetic studies, including genome-wide
association studies and Immunochip analysis, have
identiﬁed several immune-related loci underlying
the susceptibility to SSc onset.2 3 Although great
advances have been made over the last 7 years, our
knowledge of SSc genetic background is still
limited, and the numbers of convincingly SSc
genetic markers only account for a small propor-
tion of the total genetic variance for the disease.4 5
Thus, further genetic studies will help to better
understand the pathogenic processes implicated in
SSc development.
A recent ﬁne-mapping genetic study of a
common autoimmunity locus, TYK2-ICAM, in
rheumatoid arthritis (RA) identiﬁed three TYK2
protein-coding variants as the most likely causal
variants responsible for the signal of association in
the region. The authors also extended the results
into other autoimmune phenotypes, such as sys-
temic lupus erythematosus (SLE), and observed
that the three variants are missense mutations pre-
dicted to be damaging using functional prediction
tools.6
TYK2 encodes a tyrosine kinase member of the
JAK-STAT family, and mediates signalling of differ-
ent interleukin 12 (IL-12) family cytokines, such us
IL-12 and IL-23. Several polymorphisms in this
locus have been associated with other autoimmune
diseases, such as psoriasis, multiple sclerosis,
Crohn’s disease and ulcerative colitis.7
Interestingly, SSc Immunochip study3 found
suggestive, but not signiﬁcant, evidence of associ-
ation in TYK2 region (p values ranging from
5×10−4 to 5×10−2). Moreover, different func-
tional and genetic studies highlighted the special
relevance of IL-12/STAT4 pathway in the disease
pathophysiology.3 4 8 9 Thus, we performed a
follow-up study to further investigate whether
variations within this genomic region, including
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the three variants responsible for the association in RA and
other autoimmune phenotypes, are also involved in SSc
susceptibility.
METHODS
Study population
This study comprised a total of 7103 patients with SSc and
12 220 healthy controls of European ancestry. The 2118
patients with SSc and 4742 healthy controls from Spain and
USA enrolled in the SSc Immunochip screening phase were
obtained from the previously published SSc Immunochip study3
and additional Immunochip data for Spanish patients with SSc
and healthy controls. The validation cohort included 4985 SSc
cases and 7478 controls from independent case–control sets of
European ancestry (Germany, the Netherlands, Italy, UK and
USA).
Patients with SSc fulﬁlled the 1980 American College of
Rheumatology classiﬁcation criteria for this disease or the cri-
teria proposed by LeRoy and Medsger for early SSc.10 11 In
addition, patients were classiﬁed as having limited cutaneous
SSc or diffuse cutaneous SSc as described in LeRoy et al.12
Patients were also subdivided by autoantibody status according
to the presence of ACA or ATA.
Approval from the local ethics committees and written
informed consent from all participants were obtained in accord-
ance with the tenets of the Declaration of Helsinki.
Study design
SSc Immunochip screening phase
An initial evaluation of TYK2 region was performed in the SSc
Immunochip screening phase. We included 30 kpb spanning the
complete TYK2 gene and 10 kpb upstream and downstream
Figure 1 Association result plot for TYK2 region in the Immunochip screening phase. The p values for association (−log10 values) of each
single-nucleotide polymorphism are plotted against their physical position on chromosome 19. The lower panel shows the linkage disequilibrium
pattern at the TYK2 locus (r2 values are indicated by colour gradient).
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from this locus, from base pair 10 450 993 to 10 504 616 in
chromosome 19. The analysed genetic region comprised the
linkage disequilibrium (LD) block that completely covers TYK2
(ﬁgure 1). Quality control ﬁlters and principal component ana-
lysis were applied as described in ref. 3. We performed single-
nucleotide polymorphism (SNP) genotype imputation of the
TYK2 region as implemented in IMPUTE2 with the use of the
1000 Genomes Phase 1 reference panel.13 14 After imputation,
genotyping data for 154 SNPs were available.
Follow-up phase
Four TYK2 missense mutations were selected for validation in
independent replication cohorts: one common coding variant
(V362F (rs2304256)), two low-frequency coding variants
(P1104A (rs34536443), I684S (rs12720356)) and one rare
coding variant (A928V (rs35018800)). Finally, we performed
meta-analysis for the selected SNPs combining the cohorts from
both stages.
Genotyping methods
The genotyping of the SSc cases included in the validation
cohorts was performed with both TaqMan SNP genotyping
technology and Immunochip platform. For TaqMan genotyping
system, we used TaqMan 50 allele discrimination predesigned
assays from Applied Biosystems in a LightCycler 480 Real-Time
PCR System (Roche Applied Science, Mannheim, Germany).
Genotyping call rate was >95% for all the SNPs. The
Immunochip genotyping was performed on the Illumina iScan
system, as per Illumina protocols, in the Centre for Genomics
and Oncological Research (GENYO, Granada, Spain). Control
genotyping data partially overlapped with those from previous
Immunochip reports.15–23 If any of the four selected SNPs was
missing in a dataset, imputation was applied. Genotype imput-
ation was performed with IMPUTE2 using the 1000 Genomes
Phase 1 reference panel.13 14 The correspondence between
Immunochip (including imputed data) and TaqMan genotyping
data was >98% for all the SNPs.
Data analysis
Associations of the SNPs with SSc were evaluated by logistic
regression analysis in all the cohorts separately. Meta-analysis
was performed with inverse-variance weighting under a
ﬁxed-effects model as implemented in PLINK V.1.07 software.24
The combined analysis, including the two phases of the study,
was also performed using the inverse variance method based on
population-speciﬁc logistic regression analyses. p Values <0.05
were considered statistically signiﬁcant in the association ana-
lyses. Heterogeneity between the datasets was assessed using
Cochran’s Q test. Q values <0.05 were considered statistically
signiﬁcant. Hardy–Weinberg equilibrium (HWE) was tested for
all the validation cohorts (HWE p values <0.01 were consid-
ered to show signiﬁcant deviation from the equilibrium). None
of the included control cohorts showed signiﬁcant deviation
from HWE for all the genotyped SNPs.
To test the independence of association between each SNP, we
performed conditional logistic regression analyses as implemen-
ted in PLINK. To analyse the possible effect of A928V
(rs35018800) in conditioning analysis, a generalised null linear
model including population origin and two variants (P1104A
(rs34536443) and I684S (rs12720356)) as covariates was com-
pared against an alternative model including the same variables
and A928V (rs35018800) variant by the means of a likelihood
ratio test in R. We also assessed the different allelic combina-
tions using PLINK. Allelic combinations with a frequency
<0.5% were excluded from the analysis.
Regional association plot for TYK2 region was performed
using LocusZoom V.1.1 software (http://csg.sph.umich.edu/
locuszoom/).25 The HapMap Project phase I, II and III (CEU
populations) was used to deﬁne the LD pattern across TYK2
region, and Haploview V.4.2 software (http://www.
Table 1 Inverse variance meta-analysis of four TYK2 SNPs in seven different cohorts of patients with SSc and healthy controls (7103 patients
with SSc and 12 220 controls)
Inverse variance test
Chr SNP Minor/major Comment MAF cases MAF controls p Value OR (95% CI)* Q
19 rs34536443 (P1104A) C/G missense Pro >Ala 0.023 0.026 2.28E-03 0.80 (0.69 to 0.92) 0.13
19 rs35018800 (A928V) A/G missense Ala >Val 0.004 0.008 1.27E-03 0.59 (0.42 to 0.81) 0.34
19 rs12720356 (I684S) C/A missense Ile >Ser 0.067 0.078 2.63E-05 0.83 (0.78 to 0.91) 0.27
19 rs2304256 (V362F) A/C missense Val >Phe 0.246 0.279 3.08E-13 0.83 (0.79 to 0.87) 0.69
*OR for the minor allele.
Chr, chromosome; MAF, minor allele frequency; Q, heterogeneity value; SNP, single-nucleotide polymorphism; SSc, systemic sclerosis.
Table 2 Dependence analysis by pairwise conditioning of four TYK2 SNPs in the overall combined cohort (7103 patients with SSc and 12 220
controls)
SNP
MAF cases/
controls
Unconditioned
p value OR
*p Value:
add to
rs2304256
OR† add to
rs2304256
*p Value:
add to
rs34536443
OR† add to
rs34536443
*p Value:
add to
rs35018800
OR† add to
rs35018800
*p Value:
add to
rs12720356
OR† add to
rs12720356
rs34536443 0.023/0.026 2.28E-03 0.80 0.02 0.84 NA NA 1.51E-03 0.79 1.04E-03 0.78
rs35018800 0.004/0.008 1.27E-03 0.59 9.56E-03 0.65 1.11E-03 0.57 NA NA 1.20E-03 0.59
rs12720356 0.067/0.078 2.63E-05 0.83 0.176 0.94 5.09E-06 0.82 2.22E-05 0.83 NA NA
rs2304256 0.246/0.279 3.08E-13 0.83 NA NA 1.37E-05 0.89 4.75E-12 0.84 1.63E-07 0.86
*Single locus test p value when SNP conditioned on rs2304256/rs34536443/rs35018800/rs12720356.
†Single locus test OR when SNP conditioned on rs2304256/rs34536443/rs35018800/rs12720356.
MAF, minor allele frequency; NA, not applicable; SNP, single-nucleotide polymorphism; SSc, systemic sclerosis.
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broadinstitute.org/haploview/haploview) was used to perform
the LD plot. The statistical power of the combined analysis is
shown in online supplementary table S1, and was calculated
according to Power Calculator for Genetic Studies 2006 soft-
ware under an additive model.26
RESULTS
SSc Immunochip initial screening
The initial screening of TYK2 region performed in the SSc
Immunochip study showed several tier-two association signals at
this locus (ﬁgure 1). A common protein-coding missense variant
previously associated with SLE showed the strongest association
with the disease (V362F (rs2304256) p value=2.39×10−4,
OR=0.85).27–29 This variant and the three TYK2 protein-coding
variants responsible for the association with RA and SLE accord-
ing to Diogo et al6 were selected for follow-up in independent
validation cohorts to conﬁrm the suggestive evidence of associ-
ation found in this locus with SSc.
Follow-up phase and meta-analysis
Pooled analysis, including the ﬁve validation cohorts, revealed
signiﬁcant associations for the four TYK2 SNPs with SSc at
p<0.05 (see online supplementary table S2). The meta-analysis
combining both steps showed that TYK2 V362F (rs2304256)
variant achieved the genome-wide signiﬁcance level
(p=3.08×10−13, OR=0.83), while P1104A (rs34536443),
A928V (rs35018800) and I684S (rs12720356) remained with
signiﬁcant nominal p values (p=2.28×10−3, OR=0.80;
p=1.27×10−3, OR=0.59; p=2.63×10−5, OR=0.83, respect-
ively) (table 1). No signiﬁcant heterogeneity in the ORs among
the seven cohorts was observed. The analyses carried out for
the main SSc clinical features revealed that the observed associ-
ation signal rely on the whole disease (data not shown).
Dependence analyses
We then assessed the independence of associations by condi-
tional logistic regression analyses. Although pairwise condi-
tioning results were not conclusive (table 2), the V362F
genome-wide signiﬁcance association was lost when adding
the allelic dosage for rs3453644, rs35018800 and
rs12720356 as covariates (pcond=0.270) (table 3), supporting
that the TYK2 V362F association was dependent on the three
rare and low-frequency missense variants. Although A928V
(rs35018800) seemed not to exert an effect on V362F
(rs2304256) association, model ﬁtting test showed that the
regression model, including this rare variant as covariate had
a signiﬁcantly better likelihood than the model excluding it
(p=1.15×10−4). Allelic combination tests also conﬁrmed that
the V362F association was driven by the presence of the
minor alleles of P1104A, A928V and I684S TYK2 variants,
since no genome-wide signiﬁcant p value was observed for
the allelic model carrying only the minor allele of V362F (see
online supplementary table S3).
DISCUSSION
The overall analysis of our study reported genome-wide signiﬁ-
cance level of association for TYK2 with SSc, providing robust
evidence for the implication of this new locus in SSc
development.
The meta-analysis showed strong association for V362F
common variant, whereas the rare and low-frequency variants—
P1104A, A928V and I684S—remained with signiﬁcant nominal
association signals. Although our study was underpowered to
detect associations at the genome-wide level of signiﬁcance for
these three missense variants, dependence analyses clearly sup-
ported that V362F association was a spurious signal, driven by
P1104A, A928V and I684S. This effect is probably due to the
high D values between V362F and the three rare and low-
frequency variants.
Our ﬁndings are in accordance with the results reported by
Diogo et al,6 which narrowed down TYK2 association to the
three missense variants—P1104A, A928V and I684S—in RA
and other autoimmune diseases through a ﬁne-mapping strategy.
The results are also consistent with the predictions of
Polyphen-2 and SIFT tools, since common TYK2 missense
variant, V362F, was predicted to be benign while P1104A,
A928V and I684S were damaging mutations.30 31 In addition,
the functional effect of P1104A and I684S variants (located in
the kinase domains of the protein) has also been addressed by in
vitro studies in primary T cells, B cells and ﬁbroblasts. These
studies showed that P1104A and I684S are catalytically
impaired, leading to a reduced TYK2 activity and decreasing
pro-inﬂammatory cytokines signalling, such as IL-6 or
IL-12.32 33 Nevertheless, since the three TYK2 rare and low-
frequency variants included in the present study were selected
according to the detailed ﬁne-mapping study performed by
Diogo et al in a large RA study cohort, the genetic effect of add-
itional independent rare and low-frequency TYK2 variants
cannot be ruled out in SSc susceptibility.
Interestingly, several IL-12 pathway-related genes have been
reported to be associated with SSc: IL12RB1 and IL12RB2
(both IL-12-receptor chains), IL12A (p35 subunit of IL-12) and
STAT4 (the transcription factor of the IL-12 signalling
axis).3 4 8 9 Thus, the association of TYK2 with SSc reported in
the present study adds another piece of evidence showing the
crucial role of this IL pathway in SSc pathogenesis.
Table 3 Conditional logistic regression analysis of four TYK2 SNPs in the overall combined cohort (7103 patients with SSc and 12 220 controls)
Conditioned to
rs2304256,
rs35018800,
rs12720356
Conditioned to
rs2304256,
rs12720356,
rs34536443
Conditioned to
rs2304256,
rs35018800,
rs34536443
Conditioned to
rs34536443,
rs12720356
Conditioned to
rs35018800,
rs12720356,
rs34536443
SNP
Unconditioned
p value OR p Value OR p Value OR p Value OR p Value OR p Value OR
rs34536443 2.28E-03 0.80 6.94E-04 0.76 NA NA NA NA NA NA NA NA
rs35018800 1.27E-03 0.59 NA NA 8.60E-04 0.56 NA NA 9.39E-04 0.57 NA NA
rs12720356 2.63E-05 0.83 NA NA NA NA 4.70E-04 0.84 NA NA NA NA
rs2304256 3.08E-13 0.83 NA NA NA NA NA NA 0.091 0.94 0.270 0.97
NA, not applicable; SNP, single-nucleotide polymorphism; SSc, systemic sclerosis.
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IL-12 is a pro-inﬂammatory cytokine that induces type 1
helper T cells (Th1) and, in combination with interferon
(IFN)-γ, antagonises type 2 helper T cells (Th2) differenti-
ation.34 Serum levels of IL-12 are signiﬁcantly increased in
patients with SSc, and this overproduction has been associated
with renal vascular damage.35 In addition, functional studies
have suggested that Th1 responses may be crucial in mediating
early inﬂammatory processes in SSc. As stated above, P1104A,
A928V and I684S missense variants are damaging TYK2 muta-
tions that ultimately lead to an impaired IL-12 signalling. This
effect would be consistent with the protective effect observed
for these variants and a lower SSc susceptibility. Thus, target
therapies blocking this pathway could be an effective treatment
for the disease, such as ustekinumab, an anti-IL-12/23 p40
monoclonal antibody currently approved for the treatment of
psoriatic arthritis.36–38
Remarkably, pharmaceutical companies are setting their sight
on JAK family as therapeutic targets for the treatment of auto-
immune diseases, such as RA and type 1 diabetes, given its
central role in the signalling pathways of a wide range of cyto-
kines. Drug discovery research is focused on the development of
speciﬁc JAK protein inhibitors, such as the recently approved
JAK3 inhibitor, tofacitinib, for the treatment of RA.39 TYK2
inhibitors have also been described, although none of these
drugs have yet made it to the clinical trials.40
In summary, the present study identiﬁed TYK2 as a novel sus-
ceptibility factor for SSc. Our results, together with previous
ﬁndings, reinforce the crucial involvement of IL-12 signalling
axis in the disease development; thus, this pathway might repre-
sent an attractive therapeutic target for the treatment of SSc.
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